Biogen’s controversial Alzheimer’s drug aducanumab — which goes before an FDA Advisory Committee panel this week — should not be approved because it failed to show efficacy, said Mayo Clinic’s David Knopman, MD, who was involved in one of the aducanumab trials, and others, in Alzheimer’s & Dementia.
Cleveland Clinic researchers did not agree, saying “lack of approval would be devastating not only to patients who will lose hope but advocates and the community at large.” (Alzheimer’s & Dementia)
A novel investigational PET tracer, 18F-PM-PBB3, captured abnormal tau protein deposits in Alzheimer’s disease and frontotemporal lobar degeneration disorders with high contrast. (Neuron)
Undiagnosed, untreated sleep disorders were tied to physician burnout. (JAMA Network Open)
No significant association was found between multiple sclerosis and vitiligo, a review concluded. (Nature Scientific Reports)
The Stentrode, an endovascular motor neuroprosthesis implanted via a jugular vein, helped two severely paralyzed patients with amyotrophic lateral